Amiodarone-induced neurotoxicity

American Journal of Health-System Pharmacy

Volumn 66, Issue 6, 2009, Pages 567-569

  Willis, Mina S ^a   Lugo, Amy M ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b SOUTHERN UNIVERSITY   (United States)

Author keywords

Amiodarone; Aspirin; Cardiac drugs; Hydralazine; Isosorbide dinitrate; Metoprolol; Neurotoxicity syndromes; Simvastatin; Toxicity; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; HYDRALAZINE; ISOSORBIDE DINITRATE; METOPROLOL SUCCINATE; SIMVASTATIN; WARFARIN;

AGED; ARTICLE; ATAXIA; CASE REPORT; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; MALE; NEUROTOXICITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; BODY EQUILIBRIUM; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; TOXICITY AND INTOXICATION;

AGED; AMIODARONE; ATAXIA; HUMANS; MALE; NEUROTOXICITY SYNDROMES; POSTURAL BALANCE;

EID: 67650153277     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080196     Document Type: Article

References (28)

1. Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA. 2007; 298:1312-1322 (Pubitemid 47449439)
2. Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for practice guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2000; 114:e257-354.
3. Siddoway L. Amiodarone: guidelines for use and monitoring. Am Fam Physician. 2003; 68:2189-2196
4. Zimetbaum P. Amiodarone for atrial fibrillation. N Engl J Med. 2007; 356:935-941
5. Goldschlager N, Epstein AE, Naccarelli G et al. Practical guidelines for clinicians who treat patients with amiodarone. Arch Intern Med. 2000; 160:1741-1748 (Pubitemid 30418810)
6. Charness ME, Morady F, Scheinman MM. Frequent neurologic toxicity associated with amiodarone therapy. Neurology. 1984; 34:669-671 (Pubitemid 14143528)
7. Palakurthy PR, Iyer V, Meckler RJ. Unusual neurotoxicity associated with amiodarone therapy. Arch Intern Med. 1987; 147:881-884 (Pubitemid 17082478)
8. Krauser DG, Segal AZ, Kligfield P. Severe ataxia caused by amiodarone. Am J Cardiol. 2005; 96:1463-4.
9. Kang HM, Kang YS, Kim SH et al. Amiodarone-induced hepatitis and polyneuropathy. Korean J Intern Med. 2007; 22:225-9.
10. Katrak PH. Stroke patients: do they have a predilection for extrapyramidal side effects from amiodarone? Arch Phys Med Rehabil. 1999; 80:112-4.
11. Arnaud A, Neau JP, Rivasseau-Jonveaux T et al. [Neurological toxicity of amiodarone. 5 case reports.] Rev Med Interne. 1992; 13:419-22. In French.
12. Maciel Júnior JA. [Amiodarone neurotoxicity. Report of 3 cases.] Arq Bras Cardiol. 1989; 53:125-7. In Portuguese.
13. Manolis AS, Tordjman T, Mack KD et al. Atypical pulmonary and neurologic complications of amiodarone in the same patient. Report of a case and review of the literature. Arch Intern Med. 1987; 147:1805-9.
14. Anderson NE, Lynch NM, O'Brien KP. Disabling neurological complications of amiodarone. Aust N Z J Med. 1985; 15:300-4.
15. Hindle JV, Ibrahim A, Ramaraj R. Ataxia caused by amiodarone in older people. Age Ageing. 2008; 37:347-8.
16. Silva Oropeza E, Peralta Rosado HR, Valero Elizondo C et al. A case of amiodarone and neuromyopathy. Rev Invest Clin. 1997; 49:135-9.
17. Fernando Roth R, Itabashi H, Louie J et al. Amiodarone toxicity: myopathy and neuropathy. Am Heart J. 1990; 119:1223-5.
18. Fraser AG, McQueen IN, Watt AH et al. Peripheral neuropathy during longterm high-dose amiodarone therapy. J Neurol Neurosurg Psychiatry. 1985; 48:576-8.
19. Lim PK, Trewby PN, Storey GC et al. Neuropathy and fatal hepatitis in a patient receiving amiodarone. Br Med J. 1984; 288:1638-9.
20. Pellissier JF, Pouget J, Cros D et al. Peripheral neuropathy induced by amiodarone chlorhydrate. A clinicopathological study. J Neurol Sci. 1984; 63:251-66.
21. Meier C, Kauer B, Müller U et al. Neuromyopathy during chronic amiodarone treatment. A case report. J Neurol. 1979; 220:231-9.
22. Abarbanel JM, Osiman A, Frisher S et al. Peripheral neuropathy and cerebellar syndrome associated with amiodarone therapy. Isr J Med Sci. 1987; 23:893-5.
23. Department of Veterans Affairs. Amiodarone monitoring. www.pbm.va.gov/monitoring/amiodaron.htm (accessed 2008 Jun 30).
24. Hilleman D, Miller MA, Parker R et al. Optimal management of amiodarone therapy: efficacy and side effects. Pharmacotherapy. 1998; 18(6, pt. 2):138S-145S.
25. Vorperian VR, Havighurst TC, Miller S et al. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol. 1997; 30:791-8.
26. Loke YK, Derry S, Aronson JK. A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone. Br J Clin Pharmacol. 2004; 57:616-21.
27. Costa-Jussa FR, Jacobs JM. The pathology of amiodarone neurotoxicity. I. Experimental studies with reference to changes in other tissues. Brain. 1985; 108:735-52.
28. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239-45.